Metabolic Dysfunction-Associated Fatty Liver Disease on Distinct Microbial Communities at the Bacterial Phylum Level

被引:2
|
作者
Uojima, Haruki [1 ,2 ]
Sakaguchi, Yoshihiko [3 ]
Gotoh, Kazuyoshi [4 ]
Satoh, Takashi [5 ]
Hidaka, Hisashi [1 ]
Take, Akira [3 ]
Horio, Kazue [1 ]
Hayashi, Shunji [3 ]
Kusano, Chika [1 ]
机构
[1] Kitasato Univ, Sch Med, Dept Gastroenterol, Internal Med, Sagamihara, Japan
[2] Natl Ctr Global Hlth & Med, Dept Genome Med Sci Project, Res Inst, Ichikawa, Japan
[3] Kitasato Univ, Sch Med, Dept Microbiol, Sagamihara, Japan
[4] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Bacteriol, Okayama, Japan
[5] Kitasato Univ, Sch Allied Hlth Sci, Div Hematol, Sagamihara, Japan
关键词
Firmicutes; Liver cirrhosis; Metabolic dysfunction-associated fatty liver disease; Fecal microbial communities; Dysbiosis; GUT MICROBIOTA; STEATOSIS; SEVERITY; FIBROSIS;
D O I
10.1159/000534284
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction: Limited data are available on the correlation between microbial communities and metabolic dysfunction-associated fatty liver disease (MAFLD). This study aimed to evaluate the influence of MAFLD on diverse microbial communities. Methods: We recruited 43 patients with a nonviral liver disease. Enrolled patients were divided into two groups according to MAFLD criteria. The fecal microbial composition was evaluated using the variable V3-V4 region of the 16S ribosomal RNA region, which was amplified using polymerase chain reaction. First, we assessed the influence of MAFLD on distinct microbial communities at the bacterial phylum level. Next, the correlation between the microbial communities and diversity in patients with MAFLD was evaluated. Results: Among the enrolled participants, the non-MAFLD and MAFLD groups consisted of 21 and 22 patients, respectively. Sequences were distributed among ten bacterial phyla. The relative abundance of Firmicutes was significantly higher in the MAFLD group than in the non-MAFLD group (p = 0.014). The microbial diversity was not significantly influenced by the presence of MAFLD (Chao-1 index: p = 0.215 and Shannon index: p = 0.174, respectively); nonetheless, the correlation coefficient between the abundances of Firmicutes and microbial diversity was higher in the non-MAFLD group than in the MAFLD group. Conclusion: The presence of MAFLD increased the relative abundances of Firmicutes at the bacterial phylum level, which may cause the discrepancy between the abundances of Firmicutes and diversity in patients with MAFLD.
引用
收藏
页码:61 / 69
页数:9
相关论文
共 50 条
  • [1] From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
    Chen, Li
    WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (12) : 1253 - 1257
  • [2] Diabetes and metabolic dysfunction-associated fatty liver disease
    Davis, Timothy M. E.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 123
  • [3] LIVER FIBROSIS IN ASIANS WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
    Kim, Byung Ik
    Sohn, Won
    Kwon, Heon-Ju
    Cho, Yong Kyun
    HEPATOLOGY, 2021, 74 : 1022A - 1022A
  • [4] Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease
    Sohn, Won
    Kwon, Heon-Ju
    Chang, Yoosoo
    Ryu, Seungho
    Cho, Yong Kyun
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) : E1135 - E1148
  • [5] Metabolic dysfunction-associated fatty liver disease: a year in review
    Alharthi, Jawaher
    Gastaldelli, Amalia
    Cua, Ian Homer
    Ghazinian, Hasmik
    Eslam, Mohammed
    CURRENT OPINION IN GASTROENTEROLOGY, 2022, 38 (03) : 251 - 260
  • [6] Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?
    Feng, Gong
    Byrne, Christopher D.
    Targher, Giovanni
    Wang, Fudi
    Zheng, Ming-Hua
    LIVER INTERNATIONAL, 2022, 42 (07) : 1496 - 1502
  • [7] Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
    Bhopale, Kamlesh K.
    Srinivasan, Mukund P.
    LIVERS, 2023, 3 (04): : 597 - 617
  • [8] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi Yiwen
    Fan Jiangao
    中华医学杂志英文版, 2022, 135 (09) : 1009 - 1018
  • [9] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi, Yiwen
    Fan, Jiangao
    CHINESE MEDICAL JOURNAL, 2022, 135 (09) : 1009 - 1018
  • [10] Cardiometabolic characterization in metabolic dysfunction-associated fatty liver disease
    Perdomo, Carolina M.
    Nunez-Cordoba, Jorge M.
    Ezponda, Ana
    Mendoza, Francisco J.
    Ampuero, Javier
    Bastarrika, Gorka
    Fruhbeck, Gema
    Escalada, Javier
    FRONTIERS IN MEDICINE, 2022, 9